查看原文
其他

上市公司招聘细胞治疗全球研发SVP, 中美俩地工作

吴红岩 医药荐客 2023-12-24

We are seeking an accomplished scientific executive and experienced drug hunter as SVP, Global Research. Reporting to CSO, s/he will be responsible for shaping the organization’s overall research strategy, starting from technology development, early discovery and drug selection, translating the strategy into tactical plans to achieve the company’s goals and objectives. Utilizing our innovative platforms in autologous and allogenic cell therapy and deep scientific and clinical insights in both blood cancers and solid tumors, this executive will lead research departments in US, China and Europe and provide scientific, organizational and program leadership to advance our growing cell therapy pipeline in Oncology and Autoimmune diseases.

The successful candidate will be a highly effective, hands-on, participative leader with a successful track record of advancing programs from initial concept into clinical development and beyond. S/he will have a demonstrated ability to build and maintain a highly effective science driven organization, drive innovation with a purpose, maintain the highest scientific rigor, and establish a culture of accountability, open communication, collaboration, and the dedication to highest standards as well as the urgency to achieve the company’s scientific and business goals.

This position will be based both in US and in China with a 50/50 time split.

Key Responsibilities

Responsibilities, include, but are not limited to, the following:
·Leads talented teams to develop novel T cell and NK cell therapy platforms, optimize preclinical process development, and deliver an innovative and sustainable autologous and allogeneic cell therapy pipeline in Oncology and Autoimmune diseases from inception to preclinical development.
·Understands/Defines key technology hurdles in cell therapies (e.g. target selectivity and expression heterogeneity, host vs. graft reactions), develop innovative approaches to overcome these hurdles, and build differentiated technology platforms to ensure our long term leadership position.
·Guides department staff and project teams to develop scientific and technological blueprints that define key go/no-go decision points and resources projects according to portfolio priorities. Directs research projects with deep knowledge and scientific judgment to focus on the critical areas of inquiry and to maintain the highest standard of scientific and technical rigor.
·Demonstrates keen intellect for integrating novel science and emerging technologies at the intersection of immunology, cancer biology, cell engineering, and process development.
·Aligns and coordinates cross-functional and cross-site activities to ensure resource efficiency and timely delivery.
·Makes strategic decisions in consultation with key senior leaders to advance research projects from target selection to IND.
·Supports the evaluation and review of projects across the entire portfolio and serves as a key leader in scientific governance bodies.
·Expands the cutting-edge expertise and capacity, develops novel platforms, and grows the depth of knowledge in cell therapy research development.
·Evaluates preclinical/clinical-stage licensing and collaboration opportunities.
·Ensures the success of key external collaborations by developing focused research plan and providing appropriate collaborative support.
·Recruits/Mentors/Develops talent, providing performance feedback, training opportunities, and exposure to new assignments.
·Builds a culture of scientific excellence, teamwork, and innovation. Optimize organization structure for clarity, collaboration, and effectiveness.
Requirements
·PhD with 12+ years of directly relevant pharmaceutical industry experience in immune oncology, immunology, and/or cell therapy.
·A deep scientist with broad knowledge in immunology and/or oncology and extensive working experience in in vitro/ex vivo/in vivo T cell and/or NK biology, as evidenced by a strong publication and patent record.
·An accomplished drug hunter in biologics and/or cell therapy discovery and early development, as demonstrated by a strong track record of advancing programs to IND. A deep understanding of pre-clinical, clinical regulatory requirements, and corresponding translational endpoints to enable human studies.
·An experienced organizational leader with ability to think strategically, develop tactic plan and aggressively execute, to nurture and develop talents, and to effectively collaborate across functions and across sites with a track record of delivering project milestones within budget and timeline. Experience in leading a large research organization with more than 250 scientists.

职位资讯
中美生物医药职位汇总-202305
招聘骨骼和关节等疾病领域人才(药理和临床药理学)
质谱公司招聘CEO
上市公司招聘多肽研发质量分析副总监,多肽合成和新剂型博士
招聘首席医学官CMO
广东药企招聘商务总监和融资总监
上市公司招聘美国BD-WFH
招聘药物化学高级经理到联合创始人级别(ADC/PROTAC/多肽)
招聘酿酒酵母和工程菌发酵博士

商务资讯
转让-结直肠癌分子诊断项目
早期项目转让:小分子脑瘤和CNS新药
2023年11月国内生物医药投融资汇总
2023年10月国内生物医药投融资汇总

行业资讯
Biotech的苦日子,为什么换来CRO的好日子
工信部2022年度中国医药工业百强榜
寒冬裁员之下,如何规避和降低职业风险?
2023中国溶瘤病毒产业发展蓝皮书
综述靶向蛋白降解(TPD):PROTAC、LYTAC、分子胶、光控PROTAC...
2022年全球医药M&A总结
ADC的迭代史盘点:中国的62家合成生物初创企业外泌体行业分析报告类器官与器官芯片行业白皮书:全球49家企业,未来是CRO还是Biotech?
核药行业白皮书:梳理全球近7000条管线,在靶点、配体、核素创新中竞赛"置身Science内" - From PhD to BD(想转BD的看过来)
继续滑动看下一个

您可能也对以下帖子感兴趣

文章有问题?点此查看未经处理的缓存